Bycus Therapeutics Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 16-11-2024
- Paid Up Capital ₹ 2.33 M
as on 16-11-2024
- Company Age 4 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -71.66%
(FY 2023)
- Profit -127.36%
(FY 2023)
- Ebitda -0.67%
(FY 2023)
- Net Worth 245.63%
(FY 2023)
- Total Assets 223.60%
(FY 2023)
About Bycus Therapeutics
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 2.33 M, as per Ministry of Corporate Affairs (MCA) records.
Lavanya Sunkara, Nishanth Pasaru, and Nageswara Pulipati serve as directors at the Company.
- CIN/LLPIN
U73200TG2020PTC140175
- Company No.
140175
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Apr 2020
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Bycus Therapeutics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lavanya Sunkara  | Director | 23-Apr-2020 | Current |
| Nishanth Pasaru | Director | 23-Apr-2020 | Current |
| Nageswara Pulipati | Director | 23-Apr-2020 | Current |
Financial Performance of Bycus Therapeutics.
Bycus Therapeutics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 71.66% decrease. The company also saw a substantial fall in profitability, with a 127.36% decrease in profit. The company's net worth Soared by an impressive increase of 245.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bycus Therapeutics?
In 2023, Bycus Therapeutics had a public holding of 14.01%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dr Agri Bio Innovations Private LimitedActive 10 years 9 monthsLavanya Sunkara and Nishanth Pasaru are mutual person
Bycus Bio Sciences LlpActive 2 years 11 monthsLavanya Sunkara, Nishanth Pasaru and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Bycus Therapeutics?
Bycus Therapeutics has a workforce of 46 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bycus Therapeutics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bycus Therapeutics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
